Not finding it? Sign in to also search OpenAlex live.
-
QOL-23. Patient Reported Outcome Measures and Quality of Life from a randomized clinical trial for hypofractionated versus normofractionated chemoradiation for glioblastoma
Arthur T.J. van der Boog, Gerda Wester, Daniëlle B. P. Eekers, Tom Budiharto, Tom Rozema, Anna M E Bruynzeel, +14 more
0citations -
Sustained Improvement in Health-Related Quality of Life in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma Treated with Daratumumab, Lenalidomide, and Dexamethasone Versus Lenalidomide and Dexamethasone: Update of the Phase 3 MAIA Trial
Aurore Perrot, Thierry T.F. Facon, Shaji Kunnathu Kumar, Torben Plesner, Robert Zygmunt Orlowski, Philippe Moreau, +24 more
1citations -
Quality of life with neoadjuvant ipilimumab (IPI) and nivolumab (NIVO) versus adjuvant nivolumab in resectable stage III melanoma: 36-week data from the phase 3 NADINA trial.2024 Journal of Clinical Oncology conference-abstract Medicine Cutaneous Melanoma Detection and Management
Minke W. Lucas, Reetta Arokoski, Alexander Maxwell Menzies, Saskia M. Pulleman, Robyn P.M. Saw, Winan J. van Houdt, +14 more
2citations -
Health-Related Quality of Life in Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma: Data from the Perseus Trial of Subcutaneous Daratumumab Combined with Bortezomib, Lenalidomide, and Dexamethasone (D-VRd)
Pieter Sonneveld, Meletios Athanasios Dimopoulos, Mario Boccadoro, Hang Quach, Phoebe Joy Ho, Meral Beksaç, +38 more
1citations -
P22.14.A REPORTING STANDARDS IN RANDOMIZED CONTROLLED TRIALS WITH FAMILY CAREGIVERS IN NEURO-ONCOLOGY: A SYSTEMATIC REVIEW FROM THE RANO-CARES WORKING GROUP2024 Neuro-Oncology conference-abstract Decision Sciences Meta-analysis and systematic reviews Open access
Florien Willemijn Boele, Caroline Hertler, Paula R. Sherwood, David Cachia, Linda Dirven, Tobias Walbert, +3 more
0citations -
Methotrexate Versus Prednisone as First-Line Treatment for Pulmonary Sarcoidosis: The PREDMETH Trial2025 American Journal of Respiratory and Critical Care Medicine conference-abstract Medicine Sarcoidosis and Beryllium Toxicity Research
Vivienne Kahlmann, Marcel Veltkamp, Catharina C. Moor, Montse Janssen Bonás, Rémy L.M. Mostard, H.N.A.J. van Rijswijk, +14 more
2citations -
Long-term clinical outcome assessments in patients with tenosynovial giant cell tumor treated with vimseltinib: 1-year results from the MOTION phase 3 trial.2025 Journal of Clinical Oncology conference-abstract Medicine Musculoskeletal synovial abnormalities and treatments
Vivek A. Bhadri, Hans A. J. Gelderblom, Silvia Stacchiotti, Sebastian Bauer, Andrew J. Wagner, Michiel A. J. van de Sande, +14 more
1citations -
Danicopan As Add-on Therapy to Ravulizumab or Eculizumab in Patients with Paroxysmal Nocturnal Hemoglobinuria: Long-Term Patient-Reported Outcomes from the Phase 3 ALPHA Trial2024 Blood conference-abstract Immunology and Microbiology Complement system in diseases Open access
Caroline Irene Piatek, Jong Wook Lee, Morag Griffin, J Nishimura, Christopher Jordan Patriquin, Hubert Schrezenmeier, +9 more
2citations -
Allogeneic Hematopoietic Cell Transplantation in Patients ≤ 60 Years with Intermediate-Risk Acute Myeloid Leukemia in First Remission - Results of the Randomized Etal-1 Trial-
Martin Bornhaeuser, Christoph Schliemann, Johannes Schetelig, Christoph Röllig, Michael Krämer, Bertram Glaß, +21 more
2citations -
First results of an open-label, single arm phase II trial investigating the efficacy and safety of trifluridine/tipiracil combined with irinotecan as a second line therapy in patients with cholangiocarcinoma.2025 Journal of Clinical Oncology conference-abstract Medicine Cholangiocarcinoma and Gallbladder Cancer Studies
Linde Kehmann, Maria Angeles Gonzalez-Carmona, Marie‐Luise Berres, Dominik Paul Modest, Alexander Wree, Marino Venerito, +6 more
2citations -
Impact of rucaparib on circadian rhythms and adverse events in ovarian cancer: Insights from the MAMOC trial.2025 Journal of Clinical Oncology conference-abstract Medicine PARP inhibition in cancer therapy Open access
Deeksha Malhan, Janina Hesse, Nina Nelson, Jessica Nguyen, Ouda Aboumanify, Josefin Garmshausen, +12 more
0citations -
Efficacy, safety, and patient-reported outcomes of vimseltinib in patients with tenosynovial giant cell tumor: Results from the phase 3 MOTION trial.2024 Journal of Clinical Oncology conference-abstract Medicine Musculoskeletal synovial abnormalities and treatments Open access cited by 11 patents
William D. Tap, Vivek A. Bhadri, Silvia Stacchiotti, Sebastian Bauer, Andrew J. Wagner, Michiel A. J. van de Sande, +14 more
2citations -
A feasibility trial investigating inductive apalutamide therapy combined with radical prostatectomy in patients with locally advanced T4 high risk prostate cancer: First results of the prospective phase II INDUCTA study.2026 Journal of Clinical Oncology conference-abstract Medicine Prostate Cancer Diagnosis and Treatment
Matthias Saar, Johannes Linxweiler, Jennifer Kranz, Marco Hoffmann, S. Siemer, K. Junker, +1 more
0citations -
The NADINA trial: A multicenter, randomised, phase 3 trial comparing the efficacy of neoadjuvant ipilimumab plus nivolumab with standard adjuvant nivolumab in macroscopic resectable stage III melanoma.2022 Journal of Clinical Oncology conference-abstract Medicine Cutaneous Melanoma Detection and Management
Minke W. Lucas, J. Lijnsvelt, Saskia M. Pulleman, Richard A. Scolyer, Alexander Maxwell Menzies, Alexander C. J. van Akkooi, +13 more
47citations -
Health-related quality of life (HRQoL) in patients with newly diagnosed multiple myeloma (NDMM) eligible for transplantation and treated with isatuximab, lenalidomide, bortezomib, and dexamethasone (Isa-RVd) versus rvd alone: Results from part 1 of the GMMG-HD7 study
Roland Schroers, Lisa Beatrice Leypoldt, Christof Scheid, Evgenii Shumilov, Christoph Lutz
0citations -
Oral Iptacopan Monotherapy Leads to Long-Term Improvements in Patient (Pt)-Reported Health-Related Quality of Life (HRQoL) and Investigator-Assessed Signs and Symptoms of Paroxysmal Nocturnal Hemoglobinuria (PNH): 48-Week (Wk) Results from the Phase III APPLY-PNH and APPOINT-PNH Trials
Antonio Maria Risitano, Bing Han, Austin Gladston Kulasekararaj, Yasutaka Ueda, Phillip Scheinberg, Jaroslaw Pawel Maciejewski, +7 more
2citations -
P1149 Guselkumab improves health-related quality of life as measured by PROMIS-29 in participants with moderately to severely active Crohn’s disease: Phase 3 GRAVITI study2025 Journal of Crohn s and Colitis conference-abstract Biochemistry, Genetics and Molecular Biology Inflammatory Bowel Disease Open access
Bruce E. Sands, Silvio Danese, Qian Cao, Flávio Steinwurz, Jarosław Kierkuś, Chenglong Han, +5 more
0citations -
ABSTRACT NUMBER: ESOC2026A1374 EFFECT OF BASELINE PERFUSION IMAGING PARAMETERS ON ENDOVASCULAR TREATMENT OUTCOMES IN MEDIUM OR DISTAL VESSEL OCCLUSION STROKE: A SECONDARY ANALYSIS OF THE DISTAL TRIAL2026 European Stroke Journal conference-abstract Medicine Acute Ischemic Stroke Management Open access
Vera Aebischer, Sterre Dassen, Julie Staals, Adriaan van Es, Gregory W. Albers, Jeremy Josef Heit, +4 more
1citations